肝动脉栓塞化疗术治疗原发性肝癌的临床研究

Abstract
Figure/Table
References (15)
Related Citation (11)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of hepatic arterial chemoembolization in the treatment of primary liver cancer.Methods A total of 100 patients with primary liver cancer who were admitted to our hospital from January 2010 to May 2014 were selected as the study subjects and randomly divided into observation group and control group,50 patients in each group.The patients in the observation group were treated with hepatic arterial chemoembolization for clinical treatment.The patients in the control group were treated with supportive therapy for clinical treatment.After the end of treatment,the clinical efficacy,progression-free survival(PFS),overall surviva(OS),and incidence rate of adverse reactions were observed and recorded in both groups,and comparative analysis was carried out.Results There was no significant difference in objective remission rate and disease control rate between the two groups(P＞0.05);the mean values of PFS and OS in the observation group was(11.25±0.84)months and(18.57±0.99)months respectively.The control group was(7.51±0.67)months and(17.03±0.89)months respectively.The comparative analysis showed that the observation group was significantly higher than that in the control group in terms of the mean value of PFS(P＜0.05).However,there was no significant difference in the mean value of OS(P＞0.05);both groups showed different degrees of adverse reactions.The incidence rate of nausea and vomiting was higher in the observation group than that in the control group(P＜0.05);all adverse reactions were relieved or disappeared after symptomatic treatment,and there was no serious effects on the treatment for patients.Conclusion Hepatic arterial chemoembolization has a significant therapeutic effect in the treatment of primary liver cancer.The treatment method can effectively improve the patient′s survival status,increase the patient′s survival time and survival rate,so it is worthy of learning and promotion in the clinical practice.

Key words： Hepatic arterial chemoembolization Primary liver cancer Supportive treatment Survival analysis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Zuo-bo
	LIU Qiu-fang
	HONG Ke-zhong

Cite this article:

CHEN Zuo-bo,LIU Qiu-fang,HONG Ke-zhong. Clinical study of hepatic arterial chemoembolization in the treatment of primary liver cancer[J]. 中国当代医药, 2018, 25(14): 66-68.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I14/66

[1]	包长斌，刘明涛，蒋林，等.肝动脉化疗栓塞术治疗中晚期原发性肝癌的疗效分析[J].重庆医学，2012，41（32）：3424-3425.
[2]	冯超，赵剑波，陈勇，等.原发性肝癌切除术后预防性经肝动脉介入治疗：肝动脉化疗栓塞术和化疗灌注术比较[J].介入放射学杂志，2014，23（8）：679-682.
[3]	姚华雄，王超，李岽健，等.TACE联合放疗治疗原发性肝癌合并门静脉癌栓疗效研究[J].中国普通外科杂志，2012，21（7）：893-895.
[4]	苏飞，王欣，陈双倩，等.经肝动脉化疗栓塞术联合无水乙醇瘤内注射治疗原发性肝癌的Meta分析[J].中华实验外科杂志，2014，31（7）：1553-1555.
[5]	刘良浩，朱云凯，张军，等.肝动脉化疗栓塞术治疗中晚期原发性肝癌体会[J].皖南医学院学报，2012，31（2）：141-143.
[6]	郑荣寿，张思维，吴良有，等.中国肿瘤登记地区2008年恶性肿瘤发病和死亡分析[J].中国肿瘤，2012，21（1）：1-12.
[7]	周俭，朱应合，杨迪，等.肝动脉化疗栓塞术联合重组血管内皮抑制素治疗原发性肝癌的疗效观察[J].中国现代医学杂志，2013，23（36）：87-90.
[8]	赵娜，纪璐，王晓燕.肝癌肝动脉化疗栓塞术患者自我效能、社会支持与生活质量的关系[J].肝胆外科杂志，2017，25（3）：230-231，238.
[9]	吴晓泉，朱力平.西黄丸联合肝动脉化疗栓塞术对晚期肝癌患者生存预后的影响分析[J].江西医药，2016，51（8）：774-775.
[10]	王阳.原发性肝癌应用复方苦参注射液联合肝动脉灌注化疗栓塞术治疗的临床探讨[J].中国处方药，2016，14（4）：91-92.
[11]	陈丽.癌平丸联合肝动脉栓塞化疗术治疗中晚期肝癌临床研究[J].中医学报，2016，31（1）：23-25.
[12]	刘天保，刘占河，吴玉叶.经导管肝动脉化疗栓塞术治疗中晚期原发性肝癌患者的疗效与安全性再认识[J].实用肝脏病杂志，2017，20（4）：507-508.
[13]	邓燕贤.肝动脉灌注化疗栓塞对肝癌患者免疫功能的影响[J].华夏医学，2016，29（1）：197-200.
[14]	黄永东，张振岳，毛健，等.原发性肝癌伴动静脉瘘的介入栓塞治疗[J].现代消化及介入诊疗，2015，20（1）：12-15.
[15]	李守帅，郑晨.原发性肝癌肝动脉化疗栓塞术联合二期手术切除的临床探讨[J].肝脏，2017，22（7）：620-623.